Significance of the study:
It has been shown earlier that antagonizing angiotensin II type I receptor (AT1R) expression may prolong mammalian life span. Further, it has been shown that disruption of AT1R (AGTR1) gene results in marked prolongation of mammalian lifespan.
From research findings to therapeutic opportunity:
This study suggests, for the first time, that Ruxolitinib (Trade name: Jakavi), by increasing the expression of its target genes, it may decrease the expression of AT1R.
And, thereby, it may: (1) decrease blood pressure; (2) decrease blood sugar levels; (3) inhibit pulmonary fibrosis; (4) enhance bacterial immunity; (5) inhibit myocardial infarction; (6) decelerate ageing process; and (4) extend the lifespan of an individual. Thus, pharmacological formulations encompassing “Ruxolitinib (Trade name: Jakavi) or its analogues, either alone or in combination with other anti-ageing/longevity promoting compounds” may be used to extend the lifespan of an individual (Figures 1-2).
Details of the research findings:
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does Ruxolitinib (Trade name: Jakavi) suppress the expression of angiotensin II type I receptor (AT1R)?
For purchase and payment details, you may reach us at firstname.lastname@example.org
# Research cooperation
Citation: Boominathan, L., Lifespan extension therapy: Ruxolitinib (Trade name: Jakavi), a drug used in the treatment of Myelofibrosis, prolongs mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 30/August/2017, 12.06 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com